

DAFTAR PUSTAKA

- Alshuwaykh,O., Cheung,A., Goel,A., Kwong,A., Dhanasekaran,R., Ghaziani,T.T., Ahmed,A., et al. (2022). Clinical Characteristics and Outcomes in those with Primary Extrahepatic Malignancy and Malignant Ascites. *BMC Gastroenterology*, 22(1), 410, pp.1-9. DOI: [10.1186/s12876-022-02487-4](https://doi.org/10.1186/s12876-022-02487-4)
- Anis,M., and Irshad,A. (2011). Imaging of Hepatocellular Carcinoma : Practical Guide to Differential Diagnosis. *Clinics in Liver Disease*;15(2):pp.335-52. Available from : <https://www.sciencedirect.com/science/article/abs/pii/S1089326111000158?via%3Dihub>
- Amalia,A., Latief,N., Murtala,B., Zainuddin,A.A., Daud,N.A. (2019). Factors Affecting Tumor Response to Transarterial Chemoembolization (TACE) Therapy in Patient with Hepatocellular Carcinoma (HCC). *Journal of Medical Sciences*, 52(2), pp.144-152. <http://dx.doi.org/10.19106/JMedSci005202202006>
- Babu,CSR, Sharma,M. (2014). Biliary Tract Anatomy and its Relationship with Venous Drainaged. *Journal of Clinical and Experimental Hepatology*;4(S1),pp.518-26
- Bruix,J., and Sherman,M. (2011). Management of Hepatocellular Carcinoma : An Update. *Hepatology*;53(3),pp.1020-22. Available from : <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084991/pdf/hep0053-1020.pdf>
- Cahyono,J.B.S.B.(2019).Tatalaksana Klinis di Bidang Gastro dan Hepatologi. *Sagung Seto*;2,pp.837 - 40.
- Cheng,A.L, Amarapurkar,D., Chao,Y., Chen,P.J., Geschwind,J.F., Goh,K.L, Han K.H., et al. (2014). Re-evaluating Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma : Consensus Recommendations and Review by an International Expert Panel. *Liver International*, 34:pp.174-83. doi : 10.1111/liv.12314
- Choi,M.H., Park,G.E., Oh,S.N., Park,M.Y., Rha,S.E., Lee,Y.J., Jung,S.E. (2018). Reproducibility of mRECIST in Measurement and Response Assessment

for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization. *Academic Radiology*,25(11),pp.1363-1373.

Choi,J., Lee,D., Shim,J.H., Kang,K.M., Lim,Y.S, Lee,Y.S., Lee,H.C. (2020). Evaluation of Transarterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma. *Plos One*,15(3),pp.1-13.
doi : <https://doi.org.10.1371/journal.pone.0229696>.

Dahlan,M.S. (2016). Besar Sampel dan Cara Pengambilan Sampel dalam Penelitian Kedokteran dan Kesehatan. Seri 2, Edisi 4. Jakarta

Ellis,H. (2011). Anatomy of the Liver. *Surgery*. Elsevier, 29(12):pp.1-4

El-Serag,H.B., Marrero,J.A., Rudolph,L., Reddy,K.R. (2008). Diagnosis and Treatment of Hepatocellular Carcinoma. *Gastroenterology*,134(6):pp.1752-63. Available from :
<https://www.gastrojournal.org/action/showPdf?pii=S0016-5085%2808%2900426-5>

European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. (2012). EASL-EORTC Clinical Practice Guidelines : Management of Hepatocellular Carcinoma. *Journal of Hepatology*,56:pp.908-43. Available from :
<https://www.journal-of-hepatology.eu/action/showPdf?pii=S0168-8278%2811%2900873-7>

Elsahhar,A., Abdelwahab,S.M., Nasser,H.M., Hassan,M.S. (2021). Assessment of the Relationship Between Hepatocellular Carcinoma Location and Its Response to Transarterial Chemoembolization. *Egyptian Journal of Radiology and Nuclear Medicine*, 52,220, pp.1-7. DOI:[10.1186/s43055-021-00601-2](https://doi.org/10.1186/s43055-021-00601-2)

Fournier,L., Ammari,S., Thiam,R., Cuenod,C.A. (2014). Imaging Criteria for Assessing Tumour Response : RECIST, mRECIST, Cheson. *Diagnostic and Interventional Imaging*. Elsevier Masson SAS,95:pp. 689-703.
Available from :

<https://reader.elsevier.com/reader/sd/pii/S2211568414001569?token=>

Grandhi,M.S., Kim,A.K., Ronnekleiv-Kelly,S.M., Kamel,I.R., Ghasebeh,M.A, Pawlik,T.M. (2016). Hepatocellular Carcinoma : From Diagnosis to

Treatment. *Surgical Oncology*. Elsevier Limited,25(2):pp.74-85.

DOI: [10.1016/j.suronc.2016.03.002](https://doi.org/10.1016/j.suronc.2016.03.002)

Hyun,D., Shin,S.W., Cho,S.K., Park,K.B., Park,H.S, Choo,S.W., Do,Y.S., et al. (2014). Efficacy of RECIST and mRECIST criteria as prognostic factors in patients, undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. *Acta Radiologica*,56(12),pp.1-9. DOI: [10.1177/0284185114560937](https://doi.org/10.1177/0284185114560937)

Hsu,CY., Lee,YH., Huang,YH., Hsia,CY., Su,CW., Lin,HC., Lee,RC., et al.(2013). Ascites in Patients with Hepatocellular Carcinoma : Prevalence, Associated Factors, Prognostic Impact, and Staging Strategy. *Hepatol Int*,7,pp.188-198. DOI [10.1007/s12072-011-9338-z](https://doi.org/10.1007/s12072-011-9338-z)

Idee,J.M., Guiu,B. (2013). Use of Lipiodol as a Drug-Delivery System for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma : a Review. *Critical Reviews in Oncology/Hematology*. Elsevier Ireland Ltd,88 (3):pp.530-49. DOI: [10.1016/j.critrevonc.2013.07.003](https://doi.org/10.1016/j.critrevonc.2013.07.003)

Ismail,B.E.S., Cabrera,R. (2013). Management of Liver Cirrhosis in Patients with Hepatocellular Carcinoma. *Chinese Clinical Oncology*,2(4),pp1-19. DOI: [10.3978/j.issn.2304-3865.2013.09.03](https://doi.org/10.3978/j.issn.2304-3865.2013.09.03)

Jin,Z.C., Chen,L., Zhong,B.Y., Zhu,H.D, Zeng,C.H, Li,R., Guo,J.H., et al. (2021) Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. *Frontiers in Oncology*, 11:pp.1-8.

Juffrie,M., Soenarto,S.S.Y., Oswari,H. (2012). Buku Ajar Gastroenterologi-Hepatologi. *Ikatan Dokter Anak Indonesia (IDAI)*,1:pp.285.

Katayama,K., Imaia,T., Abea,Y., Nawaa,T., Maedab,N., Nakanishib,K., Wadac,H., et al. (2018). Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis. *J Clinic Med Res*,10(10),765-771.

Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/1355/2022 Tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Karsinoma Sel Hati pada Dewasa. Available

from:

[https://yankes.kemkes.go.id/unduh/fileunduh_1664864202_179501.](https://yankes.kemkes.go.id/unduh/fileunduh_1664864202_179501.pdf)

pdf

Khorsandi,S.E., Heaton N. (2012). Contemporary Strategies in the Management of Hepatocellular Carcinoma. *HPB Surgery, Hindawi Publishing Corporation*,2012:pp.1-8. doi: 10.1155/2012/154056.

Kim,G.H., Kim,J.H., Shim,J.H. Ko,HK., Chu,H.H., Shin,J.H., Yoon,H.K., et al. (2021). Chemoembolization for Single Large Hepatocellular Carcinoma with Preserved Liver Function : Analysis of Factors Predicting Clinical Outcomes in a 302 Patient Cohort. *Life (Basel)*,11(8),840, pp.1-13. doi: 10.3390/life11080840.

Kotsifa,E., Vergadis,C., Vailas,M., Machairas,N., Kykalos,S., Damaskos,C., Garpis,N., et al. (2022). Transarterial Chemoembolization for Hepatocellular Carcinoma : Why, When, How ?. *Journal of Personalized Medicine*,12:pp.436.

Kuiper,J.J., De Man,R.A., Buuren,H.R. (2007). Review Article : Management of Ascites and Associated Complications in Patients with Cirrhosis. *Alimentary Pharmacology & Therapeutics*, 26(Suppl 2), pp.183-193. doi:10.1111/j.1365-2036.2007.03482.x

Ling,Y.H., Chen JW., Wen,SH., Huang,CY., Li,P., Lu,LH., Mei,J. (2020). Tumor Necrosis as a Poor Prognostic Predictor on Postoperative Survival of Patients with Solitary Small Hepatocellular Carcinoma. *BMC Cancer*, 20,607, pp.1-9.

Liu P., Xie SH, Hu S., Cheng X., Gao T., Zhang C., Zifang L.(2017). Age-Specific Sex Difference in the Incidence of Hepatocellular Carcinoma in the United States. *Oncotarget*,8(40),68131-7. DOI: [10.18632/oncotarget.19245](https://doi.org/10.18632/oncotarget.19245)

Ly,W.F., Liu,K.C., Lu,D., Zhou,C.Z., Cheng,DL., Xiao,JK, Zhang,XM, et al. (2018). Transarterial Chemoembolization for Hepatocellular Carcinoma

Combined with Portal Vein Tumor Thrombosis. *Cancer Management and Research*,10,pp.4719-26. Doi : 10.2147/CMAR.S166527

- Meriggi,F., Graffeo,M. (2021). Clinical Characterisation and Management of the Main Treatment – Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. *Cancers*; 13(3):pp. 1-19. doi: [10.3390/cancers13030584](https://doi.org/10.3390/cancers13030584)
- Osman M.F., Farag A.S.A., Samy H.A., et al. (2021). Role of Multislice Computed Tomography 3D Volumetric Analysis in the Assessment of the Therapeutic Response of Hepatocellular Carcinoma After Transarterial Chemoembolization. *Egyptian Journal of Radiology and Nuclear Medicine*,52(177),1-10. <https://doi.org/10.1186/s43055-021-00542-w>
- Padhya,K.T, Marrero,J.A., Singal,A.G. (2013). Recent Advances in the Treatment of Hepatocellular Carcinoma. *Current Opinion in Gastroenterology*;29(3):pp.285-92. Available from : https://journals.lww.com/co-gastroenterology/Abstract/2013/05000/Recent_advances_in_the_treatment_of_hepatocellular.9.aspx
- Patel,T., Harnois,D. (2014). Assessment of Response to Therapy in Hepatocellular Carcinoma. *Annals of Medicine*; 46:pp.130-7.
- Pomej,K., Scheiner,B., Harti,L., Balcar,L., Meischl,T., Mandorfer,M., Reiberger,T., et al. (2021). COVID-19 Pandemic : Impact on the Management of Patients with Hepatocellular Carcinoma at a Tertiary Care Hospital. *Plos One*;16(8):pp.1-14. <https://doi.org/10.1371/journal.pone.0256544>.
- Rabouhans,J.S., Baron,A., Cazejust,J., Rosmorduc,O., Menu,Y. (2011). A Radiologist’s Guide to the Modified Response Evaluation Criteria in Solid Tumours (mRECIST) Assessment of therapy for Hepatocellular Carcinoma. *European Society of Radiology Electronic Presentation Online System, Poster C-2*,pp.1-42. Available from : <https://epos.myesr.org/poster/esr/ecr2011/C-2120>
- Sakuraoka,Y., Kubota,K., Tanaka,G., Shimizu,T., Tago,K., Hwa,T.K., Matsumoto,T. (2020). Is Left-Sided Involvement of Hepatocellular

Carcinoma an Important Preoperative Predictive Factor of Poor Outcome?.

World Journal of Surgical Oncology,18(1),pp.1-9. doi: 10.1186/s12957-020-02100-6

Sastroasmoro,S. & Ismael,S. (2011). Dasar-dasar Metodologi Penelitian Klinis.

Usulan Penelitian. *In S. Sastroasmoro & S. Ismael, eds.* Jakarta:Sagung Seto,pp.31-63.

Sato,Y., Watanabe,H., Sone,M., Onaya,H., Sakamoto,N., Osuga,K., Takahashi,M, et al. (2013). Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602. *Upsala Journal of Medical Sciences*,118(1):pp.16–22. doi: [10.3109/03009734.2012.729104](https://doi.org/10.3109/03009734.2012.729104)

Shin,S.W. (2009). The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. *Korean Journal of Radiology*,10(05):pp.425. doi: [10.3348/kjr.2009.10.5.425](https://doi.org/10.3348/kjr.2009.10.5.425)

Sieghart,W., Hucke,F., Peck-Radosavljevic,M. (2015). Transarterial Chemoembolization : Modalities, Indication, and Patient Selection. *Journal of Hepatology*. European Association for the Study of the Liver;62(5):pp.1187-95. DOI: [10.1016/j.jhep.2015.02.010](https://doi.org/10.1016/j.jhep.2015.02.010)

Tacher,V., Lin,M.D., Duran,R., Yarmohammadi,H., Lee,H., Chapiro,J., Chao,M., et al. (2016). Comparison of Existing Response Criteria in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Using a 3D Quantitative Approach. *Vascular and Interventional Radiology*,278(1):pp.275-84. <https://doi.org/10.1148/radiol.2015142951>.

Vesselle,G., Quirier-leleu,C. Velasco,S., Charier,F., Silvain,C., Boucebc, S., Ingrand,P., et al. (2015). Predictive Factors for Complete Response of

Chemoembolization with Drug-Eluting Beads (DEB-TACE) for
Hepatocellular Carcinoma. *European Radiology*, 100, pp.1-9.

Villanueva, A. (2019). Hepatocellular Carcinoma. *The New England Journal of
Medicine*, 380: pp.1450-62.

Wan L., Dong DH., Wu X.N., Ding H.F., Lu Q., Yongtian, Zhang XF, et al. (2020).
Single Large Nodule (>5cm) Prognosis in Hepatocellular Carcinoma :
Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?.
Medical Science Monitor, 26, pp.e9267911 - e9267917.

Wible, B.C. (2018). Diagnostic Imaging : Interventional Procedures. Elsevier, 2: pp.
588-99.

World Health Organization (WHO). (2020). Indonesia. *Global Cancer
Observatory (Globocon)*, International Agency for Research on Cancer.
Available from : [https://gco.iarc.fr/today/data/factsheets/populations/360-
indonesia-fact-sheets.pdf](https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf)

Young, S., Craig P., Golzarian J. (2019). Current Trends in the Treatment of
Hepatocellular Carcinoma with Transarterial Embolization : a Cross-
Sectional Survey of Techniques. *European Society of
Radiology*, 29: pp.3287-95. doi: [https://doi.org/10.1007/s00330-018-5782-
7](https://doi.org/10.1007/s00330-018-5782-7)

Zhang CH., Cheng Y., Zhang S., Fan J., Qiang G. (2021). Changing Epidemiology
of Hepatocellular Carcinoma in Asia. *Liver International*, pp.2029-41.
DOI: 10.1111/liv.15251.

Zhong, B.Y., Jin, Z.C., Chen, J.J., Zhu, H.D., Zhu, X.L. (2023). Role of Transarterial
Chemoembolization in the Treatment of Hepatocellular Carcinoma.
Journal of Clinical and Translational Hepatology, 11(2): pp.480-9.